Amal Chandra Mondal

Dr. Amal Chandra Mondal

School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
MAMir Hilal Ahmad
Mir Hilal Ahmad
MFMahino Fatima
Mahino Fatima
Amal Chandra MondalAmal Chandra Mondal
Amal Chandra Mondal

2 January 2023 in Ageing Research Reviews
Verified
Journal Article
Closed access
MAMir Hilal Ahmad
Mir Hilal Ahmad
MRMoshahid Alam Rizvi
Moshahid Alam Rizvi
MAMansoor Ali
Mansoor Ali
Amal Chandra MondalAmal Chandra Mondal
Amal Chandra Mondal

27 November 2018 in International Journal of Neuroscience
Verified
Journal Article
Closed access
Amal Chandra MondalAmal Chandra Mondal
Amal Chandra Mondal
MFMahino Fatima
Mahino Fatima
Depression is one of the most prevalent, recurrent and life-threatening mental illnesses. However, the precise mechanism underlying the disorder is not understood yet. It is therefore, essential to identify the symptoms and then discover the novel biomarkers which will help in the diagnosis and the development of effective treatment. In this milieu, number of preclinical and clinical studies suggest that several neurotrophic factors, including the brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) play an important role in the pathophysiology of major depression. Previously, we have reported that BDNF level in the brain of suicide victims was significantly lower than those of normal controls. We have also shown decreased BDNF levels in the specific brain regions of the learned helplessness model of depression in rat. This was increased to the normal level following chronic fluoxetine hydrochloride treatment. NGF is another important neurotrophin, which is dysregulated in the pathophysiology of depression in some animal models of peripheral nerve damage and stress. But some recent results have shown conflicted preclinical and clinical evidences on the effect of ADs treatment on modulating depression via NGF, therefore making it difficult to affirm the therapeutic role of antidepressants (ADs). Here, we review some of the preclinical and clinical studies aimed at disclosing the role of BDNF and NGF mediating pathophysiological mechanisms of depression and the new therapeutic approaches targeting these molecules. In addition, an important link between BDNF, NGF in depression and ADs treatment has been discussed in the light of current existing knowledge.

1 August 2005 in Biological Psychiatry
Verified
Journal Article
Closed access
YDYogesh Dwivedi
Yogesh Dwivedi
Amal Chandra MondalAmal Chandra Mondal
Amal Chandra Mondal
HRHooriyah S. Rizavi
Hooriyah S. Rizavi
RCRobert R. Conley
Robert R. Conley

1 February 2009 in Biological Psychiatry
Verified
Journal Article
Closed access
YDYogesh Dwivedi
Yogesh Dwivedi
HRHooriyah S. Rizavi
Hooriyah S. Rizavi
HZHui Zhang
Hui Zhang
Amal Chandra MondalAmal Chandra Mondal
Amal Chandra Mondal
RRRosalinda C. Roberts
Rosalinda C. Roberts
GPGhanshyam N. Pandey
Ghanshyam N. Pandey

4 April 2017 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
MFMahino Fatima
Mahino Fatima
SSSaurabh Srivastav
Saurabh Srivastav
Amal Chandra MondalAmal Chandra Mondal
Amal Chandra Mondal